Back to Search Results

Biomarkers of GH action in children and adults.

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany. Electronic address: katharina.schilbach@med.uni-muenchen.de. Department of Internal medicine and clinical nutrition, Sahlgrenska academy, University of Gothenburg, Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden. Department of Pediatrics, Endocrine Division (SEMPR), Federal University of Paraná, Curitiba, Brazil. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2018;:1-8
Full text from:

Other resources

Abstract

Growth hormone (GH) and IGF-I levels in serum are used as biomarkers in the diagnosis and management of GH-related disorders but have not been subject to structured validation. Auxological parameters in children and changes in body composition in adults, as well as metabolic parameters and patient related outcomes are used as clinical and surrogate endpoints. New treatment options, such as long acting GH and GH antagonists, require reevaluation of the currently used biochemical biomarkers. This article will review biomarkers, surrogate endpoints and clinical endpoints related to GH treatment in children and adults as well as in acromegaly.

Methodological quality

Publication Type : Review

Metadata